These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 18822831

  • 1. Medications for adolescents with attention-deficit/hyperactivity disorder.
    Soileau EJ.
    Adolesc Med State Art Rev; 2008 Aug; 19(2):254-67, viii-ix. PubMed ID: 18822831
    [Abstract] [Full Text] [Related]

  • 2. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B, Sopko MA, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT.
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [Abstract] [Full Text] [Related]

  • 3. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL.
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [Abstract] [Full Text] [Related]

  • 4. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA, Pliszka SR.
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [Abstract] [Full Text] [Related]

  • 5. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B.
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [Abstract] [Full Text] [Related]

  • 6. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P.
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.
    Hennessy S, Schelleman H, Daniel GW, Bilker WB, Kimmel SE, Guevara J, Cziraky MJ, Strom BL.
    Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):934-41. PubMed ID: 20623519
    [Abstract] [Full Text] [Related]

  • 8. Psychopharmacology of ADHD in adolescents.
    Greydanus DE, Sloane MA, Rappley MD.
    Adolesc Med; 2002 Oct; 13(3):599-624. PubMed ID: 12270803
    [Abstract] [Full Text] [Related]

  • 9. Dexmethylphenidate for attention deficit hyperactivity disorder.
    Coury D.
    Expert Opin Pharmacother; 2009 Nov; 10(16):2679-85. PubMed ID: 19874250
    [Abstract] [Full Text] [Related]

  • 10. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.
    Kaplan G, Newcorn JH.
    Pediatr Clin North Am; 2011 Feb; 58(1):99-120, xi. PubMed ID: 21281851
    [Abstract] [Full Text] [Related]

  • 11. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
    Harpin VA.
    Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307
    [Abstract] [Full Text] [Related]

  • 12. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence.
    Brown RT, Amler RW, Freeman WS, Perrin JM, Stein MT, Feldman HM, Pierce K, Wolraich ML, American Academy of Pediatrics Committee on Quality Improvement, American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder.
    Pediatrics; 2005 Jun; 115(6):e749-57. PubMed ID: 15930203
    [Abstract] [Full Text] [Related]

  • 13. Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.
    Merkel RL, Kuchibhatla A.
    Expert Opin Drug Saf; 2009 Nov; 8(6):655-68. PubMed ID: 19785509
    [Abstract] [Full Text] [Related]

  • 14. Stimulant therapy in attention deficit/hyperactivity disorder.
    Baldwin RL.
    J Ark Med Soc; 2003 Dec; 100(6):203-6. PubMed ID: 14661403
    [Abstract] [Full Text] [Related]

  • 15. Attention deficit hyperactivity disorder in adults.
    Rösler M, Casas M, Konofal E, Buitelaar J.
    World J Biol Psychiatry; 2010 Aug; 11(5):684-98. PubMed ID: 20521876
    [Abstract] [Full Text] [Related]

  • 16. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder.
    Fone KC, Nutt DJ.
    Curr Opin Pharmacol; 2005 Feb; 5(1):87-93. PubMed ID: 15661631
    [Abstract] [Full Text] [Related]

  • 17. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H.
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [Abstract] [Full Text] [Related]

  • 18. Attention deficit/hyperactivity disorder and psychopharmacologic treatments in the athlete.
    Conant-Norville DO, Tofler IR.
    Clin Sports Med; 2005 Oct; 24(4):829-43, viii. PubMed ID: 16169448
    [Abstract] [Full Text] [Related]

  • 19. [The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents].
    Frölich J, Banaschewski T, Spanagel R, Döpfner M, Lehmkuhl G.
    Z Kinder Jugendpsychiatr Psychother; 2012 Sep; 40(5):287-99; quiz 299-300. PubMed ID: 22869222
    [Abstract] [Full Text] [Related]

  • 20. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
    Niederhofer H.
    Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.